- RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
For: Lymphoma, Non-HodgkinUnited States · Australia · Belgium - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - RecruitingPHASE2
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
This study looks at a new drug, MEN1703, alone or with another drug, glofitamab, for people with a type of aggressive non-Hodgkin lymphoma that has returned or hasn't responded to other treatments. It aims to see if these treatments are safe and help shrink the lymphoma.
For: Non-Hodgkin Lymphoma, B-cellFrance · Poland · Spain - RecruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
For: B-Cell Non-Hodgkin Lymphoma · Relapsed B-Cell Non-Hodgkin Lymphoma · Refractory B-Cell Non-Hodgkin LymphomaUnited States · Belgium · Czechia - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
For: Large B-Cell LymphomaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy
This study is looking at a new medicine called glofitamab for people with lymphoma that has come back or hasn't responded to previous treatments, including CAR T-cell therapy. It's in an early stage of testing to see how well it works and if it helps people live longer.
For: Relapse/Refractory LymphomasFrance - RecruitingPHASE2
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
This study looks at new drug combinations for large B-cell lymphoma that has come back or not responded to past treatments. It checks how safe and effective these drugs are, both before and after a treatment called CAR-T cell therapy.
For: Large B-cell LymphomaUnited Kingdom - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel